KDR and breast carcinoma: 237-239 It presents itself as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2 by binding to VEGFR2. Preclinical and clinical evidence suggests that Ramucirumab may critical roles in angiogenesis in breast cancer growth, invasion, and metastasis. 240